At a glance
- Originator Kureha Corporation
- Developer Sankyo
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 18 Aug 2003 Suspended - Phase-II for Osteoarthritis (PO)
- 31 Mar 2002 Phase-II clinical trials in Osteoarthritis (PO)